Featured Research

from universities, journals, and other organizations

Assessing The Cost Of Juvenile Arthritis

February 1, 2007
John Wiley & Sons, Inc.
A new study examined direct medical costs of children with juvenile idiopathic arthritis and found that the economic impact was substantial.

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood, yet unlike adult arthritis, little is known about its economic impact. A new study published in the February 2007 issue of Arthritis Care & Research examined direct medical costs of children with JIA and found that the economic impact was substantial.

Led by Drs. Ann Clarke, Ciaran Duffy, and Sasha Bernatsky of the McGill University Health Centre in Montreal, Quebec, the study involved 155 children with JIA and 181 controls from two hospitals in Montreal and Vancouver, Canada. Subjects' parents were given a questionnaire about the use of medications and health services during the preceding three months, without specifying any particular disease. Researchers also asked parents about time loss from their work and days missed from school for the children.

The study was the first to quantify an association between JIA disease activity and health care costs and found that the difference in annualized average direct medical costs for the JIA group versus the control group was $1,686. The JIA group also had higher costs related to specialists, health care professionals, and diagnostic tests. The authors note that the "costs were higher for JIA subjects even compared with those of clinic controls, who almost certainly had greater health resource use than the generally healthy pediatric population," adding that the controls had relatively high rates of emergency room visits, assistive devices, surgeries, and inpatient stays, probably due to the fact that some were recruited from orthopedic clinics. When comparing direct medical costs of JIA patients with recent cost estimates for asthma, JIA appeared to be more costly, mostly because of higher medication costs.

The current study does not quantify the long-term medical and social costs of having inadequately controlled arthritis in childhood. "Ongoing active inflammation and the consequent joint damage have a significant impact on the ability of an individual to be a productive member of society," the authors state. They note that the JIA patients on average had more missed days of school per year compared with the controls and point out that indirect costs, such as missed time from work, are also very important from a societal perspective.

Insight into factors that influence health care costs can play an important role in resource allocation, which is increasingly important in light of economic constraints on health care systems, the authors state.

The results of the study are important in helping to quantify the magnitude of health care cost savings that could result in better disease control, especially given the development of costly new medications, the authors state. "Ultimately, decisions regarding access to therapies should be considered in terms of overall cost-benefit ratios," they conclude. "More effective interventions, even if associated with higher initial health care costs, may well have significant long-term cost savings to society."

Article: "Economic Impact of Juvenile Idiopathic Arthritis," Sasha Bernatsky, Ciaran Duffy, Peter Malleson, Debbie Ehrmann Feldman, Yvan St. Pierre, Ann E. Clarke, Arthritis Care & Research, February 2007; (DOI: 10.1002/art.22463).

Story Source:

The above story is based on materials provided by John Wiley & Sons, Inc.. Note: Materials may be edited for content and length.

Cite This Page:

John Wiley & Sons, Inc.. "Assessing The Cost Of Juvenile Arthritis." ScienceDaily. ScienceDaily, 1 February 2007. <www.sciencedaily.com/releases/2007/01/070131090836.htm>.
John Wiley & Sons, Inc.. (2007, February 1). Assessing The Cost Of Juvenile Arthritis. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2007/01/070131090836.htm
John Wiley & Sons, Inc.. "Assessing The Cost Of Juvenile Arthritis." ScienceDaily. www.sciencedaily.com/releases/2007/01/070131090836.htm (accessed July 30, 2014).

Share This

More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins